Cowen & Co Upgrades SVNT To Outperform

by Monica Gerson, Benzinga Staff Writer

October 28, 2010 7:33 AM | 13 seconds read | Make a Comment

Analysts at Cowen & Co upgrade Savient Pharmaceuticals Inc

SVNT

from "neutral" to "outperform." The target price for SVNT is set to $19. SVNT's shares gained 10.08% to close at $12.67 yesterday.

Posted In: Upgrades Analyst Ratings Biotechnology Cowen & Co Health Care

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.